Please try another search
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Name | Age | Since | Title |
---|---|---|---|
Yu-Hsin Lin | 44 | 2018 | Chairman of the Board of Directors & CEO |
Hung-Wei Chen | 42 | 2021 | Director |
Hendrik P.N. Scholl | - | - | Member of Ophthalmology Clinical Advisory Board |
Quan Dong Nguyen | - | - | Member of Ophthalmology Clinical Advisory Board |
Robyn Guymer | - | - | Member of Ophthalmology Clinical Advisory Board |
Frank G. Holz | - | - | Member of Ophthalmology Clinical Advisory Board |
John M. Longo | 54 | 2022 | Independent Director |
Wan-Shan Chen | 37 | 2021 | Director |
Yuan Lu | 46 | 2022 | Independent Director |
Michel Michaelides | - | - | Member of Ophthalmology Clinical Advisory Board |
Hao-Yuan Chuang | 39 | 2020 | CFO & Director |
Gary C. Biddle | 71 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review